Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Theralase Technologies's retained earnings for the quarter that ended in Mar. 2026 was $-52.95 Mil.
Theralase Technologies's quarterly retained earnings
declined
from Sep. 2025 ($-51.27 Mil) to Dec. 2025 ($-51.92 Mil) and
declined
from Dec. 2025 ($-51.92 Mil) to Mar. 2026 ($-52.95 Mil).
Theralase Technologies's annual retained earnings
declined
from Dec. 2023 ($-47.14 Mil) to Dec. 2024 ($-47.38 Mil) and
declined
from Dec. 2024 ($-47.38 Mil) to Dec. 2025 ($-51.92 Mil).
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Theralase Technologies Retained Earnings Historical Data
* Premium members only.
The historical data trend for Theralase Technologies's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
What does a Retained Earnings of $-52.95 Mil mean?
Theralase Technologies (TLTFF) has a Retained Earnings of $-52.95 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Theralase Technologies and its competitors.
Is Theralase Technologies' Retained Earnings too high?
Theralase Technologies' current Retained Earnings is $-52.95 Mil. Overall, Theralase Technologies has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Retained Earnings compare to ABT and SYK?
Theralase Technologies' Retained Earnings of $-52.95 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Theralase Technologies and its competitors. Theralase Technologies's current Retained Earnings is $-52.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.19 — trading 49.1% above its estimated fair value. The current Retained Earnings is $-52.95 Mil. Theralase Technologies' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current Retained Earnings is $-52.95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TLTFF) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of $0.19 is trading 49.1% above its estimated GF Value™ of $0.13.
GuruFocus considers Theralase Technologies to be Significantly Overvalued.
Key valuation signals for TLTFF:
Retained Earnings: $-52.95 Mil
GF Value™: $0.13 vs. price of $0.19 (49.1% above fair value)
No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
46GF Score
Get the complete analysis for TLTFF
Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLTFF has been successfully added to your 
